The CH3A4A7 monoclonal antibody reacts with an extracellular epitope on human CD344 which is also known as Frizzled family receptor 4 (FZD4) or Frizzled-4. CD344 is a member of the Frizzled family of proteins within the G protein-coupled receptor (GPCR) superfamily. CD344 is a receptor for Wnt proteins and participates in the activation of the Wnt/beta-catenin pathway (canonical Wnt signaling). Patients with familial exudative vitreoretinopathy (FEVR) carry mutations in Frizzled-4. This disease is characterized by retinal degeneration and hearing loss. On tissues, CD344 is almost ubiquitously expressed. CD344 is highly expressed in adult heart and skeletal muscle.
The antibody was conjugated to BD Horizon™ BUV661 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 661-nm. BD Horizon Brilliant BUV661 can be excited by the ultraviolet laser (355 nm) and detected with a 670/25 filter and a 630 nm LP. Due to cross laser excitation of this dye, there may be significant spillover into channels detecting APC-like emissions (eg, 670/25-nm filter).
Due to spectral differences between labeled cells and beads, using BD™ CompBeads can result in incorrect spillover values when used with BD Horizon BUV661 reagents. Therefore, the use of BD CompBeads or BD CompBeads Plus to determine spillover values for these reagents is not recommended. Different BUV661 reagents (eg, CD4 vs. CD45) can have slightly different fluorescence spillover therefore, it may also be necessary to use clone-specific compensation controls when using these reagents.